Skip to main content Skip to search Skip to main navigation

EU: Procedures on Inspections and Exchange of Information in new Version 18

The European Commission has revised and restructured the Compilation of Community Procedures on Inspections and Exchange of Information. In addition to new content and editorial adjustments, the 295-page document has been divided into a Part I including procedural topics and a Part II containing interpretation documents and templates. The documents were last updated in 2014.

The compilation primarily serves a harmonised approach and to facilitate cooperation for inspections within the European Member States. It applies to both GMP and GDP inspections. The procedures outlined in the compilation in turn form the basis for national procedures that are part of the quality management systems of the national GMP inspectorates.

In Part I, these procedural topics have been revised in form of independent short documents:

  • Management and classification of reports of suspected quality defects in medicinal products and risk-based decision-making (new: provides more comprehensive guidance following quality risk management principles)
  • Procedure for managing rapid alerts arising from quality defects risk assessment
    (new: provides more comprehensive guidance following quality risk management principles)
  • Outline of a Procedure for Co-ordinating the Verification of the GMP Status of Manufacturers in Third Countries
  • The Issue and Update of GMP Certificates
  • A model for risk based planning for inspections of pharmaceutical manufacturers
  • Procedure for dealing with serious GMP non-compliance requiring co-ordinated measures to protect public or animal health (Procedure has been revised as a result of experience with the superseded procedure; Appendix 6: Supervisory Risk Assessment has been updated)
  • Procedure for dealing with serious GMP non-compliance information originating from third country authorities or international organisations

New in Part I:

  • Procedure for compliance management

In Part II revised interpretational documents and templates are:

  • Interpretation of the Union format for Manufacturer/Importer Authorisation
  • Interpretation of the Union format for GMP certificate
  • Interpretation of the Union format for a wholesale distribution authorisation (medicinal products for human use)
  • Union format for a GMP certificate
  • Statement of non-compliance with GMP

New in Part II:

  • Interpretation of the Union format for a wholesale distribution authorization (medicinal products for human use)

Source:
EU: CoCP on Inspections and Exchange of Informations

 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

IPEC: Stability Guide for Excipients has been Updated

IPEC: Stability Guide for Excipients has been Updated

The IPEC Stability Guide for Pharmaceutical Excipients has been updated and is now available as version 3 (2026), as announced on the IPEC (International Pharmaceutical Excipients Council) website.

Read more
EU: “Forever Chemicals” in a Conflict of Interests

EU: “Forever Chemicals” in a Conflict of Interests

On 14 July 2026, the European Parliamentary Research Service (EPRS) published a comprehensive briefing on PFAS (per- and polyfluoroalkyl substances), also known as ‘forever chemicals’. The document is intended to serve as a technical basis for MEPs in their upcoming political decisions on PFAS regulation and summarises the current state of scientific knowledge, regulation and procedures.

Read more
Handover of Computerised Systems to the Operating Department

Handover of Computerised Systems to the Operating Department

The GMP-compliant handover of computerised systems to operations is a critical step in the Computer System Validation (CSV) lifecycle. Beyond go-live and hypercare, clearly defined responsibilities, comprehensive documentation and well-trained personnel are essential to maintaining a validated state throughout routine operation.
Read more
How is the Effectiveness of CAPAs Verified?

How is the Effectiveness of CAPAs Verified?

Here's the answer:
Read more
APIC: Publishes Updated “How to Do” Document for GDP for Active Pharmaceutical Ingredients

APIC: Publishes Updated “How to Do” Document for GDP for Active Pharmaceutical Ingredients

The Active Pharmaceutical Ingredients Committee (APIC) has published Version 3 of the document “GDP for APIs: How to Do” (June 2026) on its website. The document provides practical guidance on implementing Good Distribution Practice for active pharmaceutical ingredients.

Read more
TGA: Seeks Feedback on Planned Adoption of 11 International Scientific Guidelines

TGA: Seeks Feedback on Planned Adoption of 11 International Scientific Guidelines

Australia's regulatory authority, the TGA (Therapeutic Goods Administration), pursues a strategy of aligning its regulatory approaches as closely as possible with comparable international standards. These include the regulatory requirements of the EU, the FDA and the ICH. In this context, around 370 international scientific guidelines have already been adopted.

Read more
Previous
Next